Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

ClinicalTrials.gov ID: NCT07121192

Public ClinicalTrials.gov record NCT07121192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a Randomized, Observer-Blind, Study to Evaluate the Immunogenicity and Safety of mRNA-Based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age And Older

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."

Study identification

NCT ID
NCT07121192
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
776 participants

Conditions and interventions

Interventions

Biological · Combination Product

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 24, 2025
Primary completion
May 10, 2026
Completion
May 10, 2026
Last update posted
May 27, 2026

2025 – 2026

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
GSK Investigational Site Anniston Alabama 36207
GSK Investigational Site Fair Oaks California 95628
GSK Investigational Site San Diego California 92120
GSK Investigational Site San Diego California 92123
GSK Investigational Site Walnut Creek California 94598
GSK Investigational Site Hialeah Florida 33012
GSK Investigational Site Jupiter Florida 33458
GSK Investigational Site Miami Florida 33186
GSK Investigational Site Stockbridge Georgia 30281
GSK Investigational Site Valparaiso Indiana 46383
GSK Investigational Site Lenexa Kansas 66219
GSK Investigational Site Springfield Massachusetts 01103
GSK Investigational Site Carson City Nevada 89706
GSK Investigational Site Rochester New York 14609
GSK Investigational Site Greensboro North Carolina 27408
GSK Investigational Site Cleveland Ohio 44122
GSK Investigational Site North Charleston South Carolina 29405
GSK Investigational Site Austin Texas 78705
GSK Investigational Site DeSoto Texas 75115
GSK Investigational Site Fort Worth Texas 76135
GSK Investigational Site Newport News Virginia 23606
GSK Investigational Site Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07121192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 27, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07121192 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →